A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

February 26, 2020
https://clinicaltrials.gov/ct2/show/NCT04164901
Cancer - Brain
Principal Investigator: Tobias Walbert, MD
AG-881, Recurrent Grade 2 Glioma, IDH1 or IDH2 Mutation
Open